Dupixent (dupilumab) approved in Japan for children aged 6 to 11 years with bronchial asthma – Sanofi
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma in children aged 6… read more.

